Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1613 - Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: initial Phase 1b results


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


David Berz


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


D. Berz1, A. Spira2, S.M. Gadgeel3, I.C. Anderson4, J.W. Goldman5, J. Thompson6, T. Foster4, Y.L. Pritchett7, C.G. Cisneros8, C. Li9, J.A. Sorrentino10, R. Malik11, A.P. Beelen12

Author affiliations

  • 1 Hematology/oncology, Beverly Hills Cancer Center, 90211 - Beverly Hills/US
  • 2 Research Institute, Virginia Cancer Specialist, 22031 - Fairfax/US
  • 3 Rogel Cancer Center, University of Michigan, Ann Arbor/US
  • 4 Hematology, St Joseph Heritage Healthcare, 95403 - Santa Rosa/US
  • 5 Medicine, David Geffen School of Medicine at UCLA, 90404 - Santa Monica/US
  • 6 Cancer Center - Froedtert Hospital, Medical College of Wisconsin, 53226 - Milwaukee/US
  • 7 Biometrics, G1 Therapeutics, Inc, NC 27709 - Research Triangle Park/US
  • 8 Clinical Operations, G1 Therapeutics, Inc, NC 27709 - Research Triangle Park/US
  • 9 Clinical Pharmacology, Clinical Development, G1 Therapeutics, Inc, NC 27709 - Research Triangle Park/US
  • 10 Biomarkers, Clinical Development, G1 Therapeutics, Inc, NC 27709 - Research Triangle Park/US
  • 11 Research And Development, G1 Therapeutics, Inc, NC 27709 - Research Triangle Park/US
  • 12 Clinical Development, G1 Therapeutics, Inc, NC 27709 - Research Triangle Park/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1613


Lerociclib (lero) is a potent, selective oral CDK4/6 inhibitor (CDK4/6i). Preclinical and early clinical data have demonstrated that lero is differentiated based on its favorable safety/tolerability profile and ability to be dosed continuously with less dose-limiting neutropenia. Encouraging preliminary efficacy has been observed in HR+/HER2- breast cancer in combination with fulvestrant (NCT#02983071). Several putative mechanisms of resistance to EGFR TKIs are upstream of the CDK4/6 pathway, and in vitro and in vivo studies with CDK4/6i + EGFR TKIs have demonstrated enhanced efficacy and delayed time to resistance. These data provide strong rationale to investigate lero + osimertinib (osi) in the clinic.


Patients with metastatic NSCLC, confirmed EGFR mutation associated with EGFR TKI sensitivity, ECOG of 0 or 1, and treatment with ≤2 lines of chemo or any EGFR TKI including osi are eligible for this phase Ib study. Patients receive lero QD or BID continuously in combination with 80 mg osi QD until disease progression. The objectives are to evaluate DLTs, safety, tolerability, PK, and anti-tumor efficacy, and to determine the dose for the randomized phase II portion of the study.


Currently, 18 patients (mean age 63 years) have been enrolled and received lero doses of 200, 300, or 400 mg QD; the longest duration being 317 days. BID enrollment is ongoing. Lero is well tolerated; no lero-related SAEs have been reported, and no patient has withdrawn due to an AE. One DLT of Grade 4 neutropenia occurred at 400 mg QD. The most common lero-related TEAEs are neutropenia and diarrhea. The incidence of diarrhea with lero + osi is similar to single agent osi (FLAURA study). There have been no reports of VTE, QT prolongation, or DILI. No clinically relevant drug-drug interaction has been observed.


The combination of continuously administered lero + osi in patients with EGFRmut NSCLC (treatment naïve or previously treated) is well tolerated with only one DLT event to date. Updated safety, anti-tumor efficacy, and cfDNA data will be presented (NCT#03455829).

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

G1 Therapeutics, Inc.


G1 Therapeutics.


D. Berz: Honoraria (self): Boehringer Ingelheim; Honoraria (self): Genentech; Honoraria (self): AstraZeneca; Honoraria (self): Merck; Honoraria (self): Tempus; Honoraria (self): Biocept; Shareholder / Stockholder / Stock options, Major Owner: Valkyrie Therapeutics. A. Spira: Advisory / Consultancy: G1 Therapeutics. J.W. Goldman: Honoraria (self), Research grant / Funding (institution): AstraZeneca. Y.L. Pritchett: Full / Part-time employment: G1 Therapeutics. C.G. Cisneros: Full / Part-time employment: G1 Therapeutics. C. Li: Full / Part-time employment: G1 Therapeutics. J.A. Sorrentino: Full / Part-time employment: G1 Therapeutics. R. Malik: Full / Part-time employment: G1 Therapeutics. A.P. Beelen: Full / Part-time employment: G1 Therapeutics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.